KP
REGN icon

Keel Point’s Regeneron Pharmaceuticals REGN Stock Holding History

Keel Point’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Sell
348
-37
-10% -$25.2K 0.01% 463
2026
Q1 		$297K Sell
385
-158
-29% -$121K 0.02% 357
2025
Q4 		$419K Buy
543
+96
+21% +$65.2K 0.03% 336
2025
Q3 		$251K Buy
+447
New +$253K 0.02% 451
2025
Q2 		– Sell
-368
Closed -$233K – 527
2025
Q1 		$233K Sell
368
-38
-9% -$26.1K 0.02% 406
2024
Q4 		$289K Sell
406
-186
-31% -$156K 0.02% 332
2024
Q3 		$622K Hold
592
– – 0.05% 202
2024
Q2 		$686K Buy
592
+152
+35% +$147K 0.06% 182
2024
Q1 		$423K Buy
440
+172
+64% +$164K 0.04% 230
2023
Q4 		$235K Buy
268
+4
+2% +$3.29K 0.03% 298
2023
Q3 		$217K Buy
+264
New +$207K 0.03% 287

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Keel Point's REGN Position: Q2 2026 in Review

Keel Point reduced its Regeneron Pharmaceuticals (REGN) stake by 9.6% in Q2 2026, selling an estimated $25.2K and leaving 348 shares worth $217K. The position accounts for 0.01% of the portfolio, ranked #463.

Keel Point first reported a position in REGN in Q3 2023 and has held it in 11 quarters since. The position peaked at $686K in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Keel Point held 348 shares of Regeneron Pharmaceuticals worth $217K as of Q2 2026.
  • Keel Point sold 37 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $25.2K.
  • Regeneron Pharmaceuticals made up 0.01% of Keel Point's portfolio in Q2 2026, its #463 holding.
  • Keel Point first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Keel Point's Regeneron Pharmaceuticals position peaked at $686K in Q2 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Keel Point's 13F filing for Q2 2026, filed 14 Aug 2026.